Maven Clinic

Leading Pharmaceuticals and Life Sciences employers are redefining what it means to support their people—delivering measurable ROI through smarter, more connected benefits. When Curia partnered with Maven to deliver family-building support—from preconception coaching and fertility cost management to maternity and return-to-work planning—the results were clear: streamlined administration, reduced vendor complexity, and measurable improvements in employee satisfaction. “My favorite part of the job is when we can offer benefits that are important to employees and make a positive impact on their lives. And I truly believe Maven has a positive impact on people’s lives. When you’re trying to start a family, you may not know where to go for resources and support. I wish I had Maven when I was younger and starting my family.” — Jodi Garofolo, Associate Director of Benefits, Curia Maven’s intelligent platform brings fertility, maternity, and menopause support together—combining clinical expertise and technology to close the gaps traditional care leaves behind. When care is scattered across apps and vendors, it drives costs up and outcomes down. Maven integrates evidence-based support and AI-powered personalization into existing health plan coverage—multiplying the impact of every benefit. The results speak for themselves: ✅ 50%+ of Maven coaching members are more likely to conceive without treatment ✅ 93% of members report menopause symptom relief within 3 months ✅ 70% of maternity members report increased productivity Discover how Maven supports the world’s leading healthcare employers → https://lnkd.in/gm5H82fk

Grateful to Employee Benefit News LIVE for this in-depth spotlight on how AI-driven early risk assessment is helping employees support maternal health before complications and costs escalate.

You’ve heard it before: “What’s the ROI?” For HR leaders building or expanding fertility benefits, that’s often the first question from the CFO. In our 4th class of Maven’s Fertility Benefits Masterclass, Katie Boehm Rooney, Chief Financial Officer at Maven Clinic, breaks down how to answer it with confidence. You’ll learn: ➡️ How fertility benefits impact overall healthcare spend ➡️ The key metrics CFOs care most about ➡️ How to make the business case for smarter, more sustainable care This session connects the dots between employee well-being and financial performance — helping you champion fertility benefits that drive value for both people and the business. 🎓 Building a Business Case and Measuring ROI is now live. Start learning at your own pace here: https://lnkd.in/gFXEEZa4

We were honored to once again be a sponsor of RESOLVE: The National Infertility Association Night of Hope Gala in New York City, an inspiring evening dedicated to supporting people navigating infertility. This event is always a powerful reminder of the strength and resilience of the family-building community, how far we’ve come in raising awareness and expanding access, and how much more there is still to do together. Grateful to RESOLVE for their continued advocacy and proud to stand alongside them in making fertility care more visible, accessible, and supported for all.

Today is World Prematurity Day. The latest March of Dimes 2025 Report Card paints a stark picture: 👉 The U.S. earned a D+ for its preterm birth rate for the fourth year in a row. 👉 Nearly 1 in 10 babies, or ~380,000 each year, are born too soon. 👉 While 19 states saw improved preterm birth rates, 21 states saw worsened rates. For families, a preterm birth can be an emotionally wrenching experience that often brings unexpected challenges, time away from work, and significant financial strain. Employers feel this impact, too, through increased healthcare costs due to long NICU stays and the challenges families face balancing care and work. At Maven, we know that investing in women's and family health is both the right thing to do and good business. We're helping families catch risks earlier, prevent complications, and recover faster. Just last week, we introduced new features designed to help reduce the risk of preterm birth linked to complications like preeclampsia and gestational diabetes and launched a new NICU program to help families bring their babies home sooner. Every family deserves the chance for a healthy start. Read the full March of Dimes 2025 Report Card, and join us in ensuring every family has the support they need—at home, at work, and every step of the way. https://lnkd.in/e4u6z8-3

This week, we’re celebrating an important milestone in Maven’s mission to improve outcomes for every family. 🎉 Maven just announced the next evolution of our Maternity & Newborn Care Program. We’ve spent more than a decade improving maternity outcomes through proven, evidence-based care. Now, we’re using predictive technology to take that impact even further— with AI-enabled tools that identify risks earlier, evidence-based programs that prevent complications, and expert support that helps families faster. It’s care that’s more predictive, proactive, and proven. Learn how we’re shaping the next era of maternity care ➡️ https://lnkd.in/eMd33CbK

For half a century, women’s bodies have carried the scars of every “miracle” weight-loss breakthrough. GLP-1 drugs, when they arrived, seemed destined to repeat that cycle — until they didn’t. Today one in eight Americans have tried a GLP-1, and most of them are women. And the truth is: they’re working. Metabolic and reproductive health are two sides of the same coin, and it’s against this backdrop that GLP-1 medications may be permanently changing the trajectory of women’s health. In this week’s Preprint, our Chief Medical Officer Neel Shah spoke with four leading obesity specialists: Dr. Fatima Cody Stanford, Dr. Holly Lofton MD, DABOM, Dr. Wendy Vitek, MD, and Dr. Aleesha Grier, Psy.D. about how they’re seeing GLP-1s in the field—and why understanding metabolism is a foundation for fertility, pregnancy, and menopause. ➡️ As a fertility doctor, Dr. Vitek used to have to turn away up to 15% of patients because of the BMI limits associated with egg retrievals. Now, she uses GLP-1s to stabilize metabolic markers before IVF — syncing two biological clocks that, for many women, have long run out of sync. ➡️ Dr. Lofton sees patients across the reproductive lifespan, but in practice many of them are women on reproductive life journeys: trying to get pregnant, trying to lose postpartum weight, or even trying to navigate menopause. Oftentimes she’s the first person to diagnose metabolic dysfunction that hides in plain sight. ➡️ Dr. Grier (who is also a provider on Maven!) has spent her career helping patients navigate weight loss transformations after gastric bypass surgeries. As she says, losing weight is never just weight—it’s also how the world perceives you, and how you perceive the world. It’s not so different from other reproductive journeys. GLP-1s are powerful tools — for everyone, but especially for women. Their impact depends on how medicine uses them: with evidence, oversight, and access. 👉 Read the full Preprint :  https://lnkd.in/gCgMBzHA

For more than a decade, Maven has supported families through every kind of pregnancy — from healthy, routine experiences to more complex, high-risk cases — improving outcomes for families and reducing costs for the employers who support them. Today, we’re taking that impact even further. Our enhanced maternity program builds on what we know works, using the largest validated dataset in digital maternity care to help make care even more predictive, precise, and personalized. With new AI-enabled population health capabilities, Maven helps identify pregnancy risks earlier, prevent and manage complications like preeclampsia and gestational diabetes, and get babies home from the NICU faster. Better care can’t wait. Today, an estimated 15% of pregnancies are considered high-risk, often leading to complications and NICU stays that take a toll on families and represent one of employers’ biggest healthcare costs. Every family deserves to feel safe and supported through pregnancy. These advancements bring us one step closer to making that a reality. Learn more: https://lnkd.in/eucympS3

At Maven, we hear from women every day about the real cost of menopause to their lives: sleepless nights from hot flashes, missed promotions from brain fog, and a body that doesn’t feel like their own. For many of these women, hormone replacement therapy (HRT) is the easiest, safest, and most effective treatment on the market. It restores energy, improves mental clarity, and protects long-term health. And for a long time, this was widely understood—until a landmark study in the 1990s linked HRT to certain cancers and heart disease. In response, the FDA issued a black-box label, and HRT’s reputation has struggled to recover. In the years since, we have learned a lot. Decades of new research have proven HRT’s safety. And while nothing about menopause is one-size-fits-all, HRT is what most often leaves our members telling us they finally “feel like themselves again.” That’s why we’re encouraged to see new FDA actions to remove HRT’s black box warning. It’s more than a policy change, it’s validation for millions of women everywhere. It’s a pivotal step forward, but true impact will come only when every doctor adopts it—and until then, Maven will continue bridging the gap for women everywhere. HRT saves lives. It improves women’s long-term health. We hope this marks the beginning of more research, more funding, more conversation, and more empathy for something all women will undergo eventually.